Patents by Inventor Mohammad R. Masjedizadeh

Mohammad R. Masjedizadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
    Patent number: 11872229
    Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: January 16, 2024
    Assignee: Principia Biopharma Inc.
    Inventors: Abu J. Ferdous, Mohammad R. Masjedizadeh, Wu Lin
  • Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-d]Pyrimidin-1-YL] Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
    Publication number: 20230399330
    Abstract: Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.
    Type: Application
    Filed: May 16, 2023
    Publication date: December 14, 2023
    Applicant: Principia Biopharma Inc.
    Inventors: Kolbot By, Katherine Chu, Mohammad R. Masjedizadeh, Pasit Phiasivongsa, Jiang Zhu
  • MODIFIED RELEASE FORMULATIONS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
    Publication number: 20210113567
    Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
    Type: Application
    Filed: October 28, 2020
    Publication date: April 22, 2021
    Applicant: Principia Biopharma Inc.
    Inventors: Abu J. FERDOUS, Mohammad R. MASJEDIZADEH, Wu LIN
  • MODIFIED RELEASE FORMULATIONS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
    Publication number: 20190231784
    Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 1, 2019
    Applicant: Principia Biopharma Inc.
    Inventors: Abu J. FERDOUS, Mohammad R. MASJEDIZADEH, Wu LIN
  • PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN
    Publication number: 20110319656
    Abstract: Methods for preparing tritium or deuterium labeled thiorphan comprising reacting a compound of formula i wherein m is from 1 to 5 and X is halo, with Z2 wherein Z is tritium or deuterium, in the presence of a catalyst, to form a compound of formula l wherein n is from 1 to 5, provided that n is less than or equal to m.
    Type: Application
    Filed: December 17, 2008
    Publication date: December 29, 2011
    Inventors: Mohammad R. Masjedizadeh, Shao-Yong Wu